INmune Bio Announces Publication In Cell Reports That Demonstrates XPro1595 Promotes Remyelination In An Animal Model Of Demyelinating Disease
Portfolio Pulse from Benzinga Newsdesk
INmune Bio, Inc. (NASDAQ:INMB) announced a publication in Cell Reports showing that their drug XPro1595 promotes remyelination in an animal model of demyelinating disease. This study has implications for CNS diseases like Alzheimer's.
October 24, 2024 | 7:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
INmune Bio's XPro1595 has been shown to promote remyelination in an animal model, which could impact treatment approaches for CNS diseases like Alzheimer's. This positive development may influence INMB's stock price.
The publication of positive results for XPro1595 in a reputable journal like Cell Reports is likely to boost investor confidence in INmune Bio's research and development capabilities. The potential application in CNS diseases, including Alzheimer's, is a significant market opportunity, which could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100